These expression profiles support the hypothesis that metabolic reprogramming modulates immune cell behavior in ARDS, with RPL14 promoting glycolysis in early macrophage activation and SMARCD3 facilitating the transition to an anti-inflammatory state (101, 102). Here, RPL14 is linked to acute respiratory distress syndrome.